NASDAQ:BBNX Beta Bionics (BBNX) Stock Price, News & Analysis $22.19 -0.62 (-2.72%) Closing price 09/23/2026 04:00 PM EasternExtended Trading$22.50 +0.31 (+1.39%) As of 04:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Beta Bionics Stock (NASDAQ:BBNX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Beta Bionics alerts:Sign Up Key Stats Today's Range$21.88▼$23.4850-Day Range$12.83▼$22.8152-Week Range$8.80▼$32.71Volume1.40 million shsAverage Volume1.35 million shsMarket Capitalization$998.33 millionP/E RatioN/ADividend YieldN/APrice Target$22.45Consensus RatingModerate Buy Company Overview Beta Bionics, Inc. is a medical technology company focused on developing automated insulin-delivery systems for people with diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to simplify diabetes management by using continuous glucose monitoring data to adjust insulin dosing with limited user input. The iLet Bionic Pancreas received clearance from the U.S. Food and Drug Administration in 2023 for use by people with type 1 diabetes. The system combines an insulin pump, dosing-control software and a compatible continuous glucose monitor, and is designed to reduce the need for users to calculate insulin doses manually. Beta Bionics also develops related technologies intended to support automated diabetes care. The company was founded by Ed Damiano, an engineering professor and researcher whose work on automated insulin delivery helped lead to the development of the iLet system. Beta Bionics is based in the United States and initially serves the U.S. diabetes-care market through its commercialized iLet product.AI Generated. May Contain Errors. Read More Beta Bionics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks22nd Percentile Overall ScoreBBNX MarketRank™: Beta Bionics scored higher than 22% of companies evaluated by MarketBeat, and ranked 808th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.4 / 5Analyst RatingModerate Buy Consensus RatingBeta Bionics has received a consensus rating of Moderate Buy. The company's average rating score is 2.54, and is based on no strong buy ratings, 8 buy ratings, 4 hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for Beta Bionics is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageBeta Bionics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Beta Bionics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Beta Bionics are expected to decrease in the coming year, from ($2.06) to ($2.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Beta Bionics is -13.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Beta Bionics is -13.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBeta Bionics has a P/B Ratio of 3.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted22.06% of the float of Beta Bionics has been sold short.Short Interest Ratio / Days to CoverBeta Bionics has a short interest ratio ("days to cover") of 9.01.Change versus previous monthShort interest in Beta Bionics has recently increased by 25.43%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBeta Bionics does not currently pay a dividend.Dividend GrowthBeta Bionics does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.21 News SentimentBeta Bionics has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 55 news articles for Beta Bionics this week, compared to 8 articles on an average week.Search InterestOnly 1 people have searched for BBNX on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat Follows1 people have added Beta Bionics to their MarketBeat watchlist in the last 30 days. Company Ownership0.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Beta Bionics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,110,394.00 in company stock.Percentage Held by Insiders5.30% of the stock of Beta Bionics is held by insiders.Percentage Held by InstitutionsBeta Bionics has minimal institutional ownership at this time.Read more about Beta Bionics' insider trading history. Receive BBNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Beta Bionics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BBNX Stock News HeadlinesBBNX Investors Have Opportunity to Lead Beta Bionics, Inc. Securities Fraud LawsuitSeptember 23 at 10:57 PM | prnewswire.comBBNX INVESTOR DEADLINE: Beta Bionics Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action LawsuitSeptember 23 at 6:09 PM | prnewswire.comTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery. | Behind the Markets (Ad)BBNX Investor Alert: Johnson Fistel Encourages Beta Bionics, Inc. Investors to Contact the Firm Ahead of November 3, 2026 Lead Plaintiff DeadlineSeptember 23 at 2:48 PM | prnewswire.comBronstein, Gewirtz & Grossman LLC Urges Beta Bionics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmSeptember 23 at 12:00 PM | globenewswire.comKaplan Fox Alerts Investors of Beta Bionics, Inc. (NASDAQ: BBNX) to a Pending Securities Class Action – Deadline is November 3, 2026September 23 at 11:00 AM | globenewswire.comMike Mensinger Sells 2,650 Shares of Beta Bionics (NASDAQ:BBNX) StockSeptember 18, 2026 | insidertrades.comBeta Bionics (NASDAQ:BBNX) Insider Sells 4,221 Shares of StockSeptember 4, 2026 | insidertrades.comSee More Headlines BBNX Stock Analysis - Frequently Asked Questions How have BBNX shares performed this year? Beta Bionics' stock was trading at $30.47 on January 1st, 2026. Since then, BBNX shares have decreased by 27.2% and is now trading at $22.19. How were Beta Bionics' earnings last quarter? Beta Bionics, Inc. (NASDAQ:BBNX) posted its quarterly earnings data on Wednesday, July, 29th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.09. The business had revenue of $32.01 million for the quarter. Beta Bionics had a negative trailing twelve-month return on equity of 26.30% and a negative net margin of 61.31%. Read the conference call transcript. When did Beta Bionics IPO? Beta Bionics (BBNX) raised $198 million in an IPO on Thursday, January 30th 2025. The company issued 12,000,000 shares at a price of $16.00-$17.00 per share. Who are Beta Bionics' major shareholders? Beta Bionics' top institutional investors include BlackRock Inc. (7.42%), Bank of America Corp DE (1.22%), Squarepoint Ops LLC (0.36%) and Bank of New York Mellon Corp (0.27%). Insiders that own company stock include Hadley Harbor Aggre Wellington, Mike Mensinger, Steven Jon Russell, Stephen Feider, Mark Hopman, Adam Lezack, Christy Jones and Maria Palasis. View institutional ownership trends. How do I buy shares of Beta Bionics? Shares of BBNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings7/29/2026Today9/23/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 BBNX's financial health is in the Green zone, according to TradeSmith. BBNX has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:BBNX Previous SymbolNASDAQ:BBNX CIK1674632 Webwww.betabionics.com Phone(949) 427-7785FaxN/AEmployees423Year Founded2015Price Target and Rating Average Price Target for Beta Bionics$22.45 High Price Target$32.00 Low Price Target$16.00 Potential Upside/Downside+1.2%Consensus RatingModerate Buy Rating Score (0-4)2.54 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($1.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$73.20 million Net Margins-61.31% Pretax Margin-61.31% Return on Equity-26.30% Return on Assets-23.25% Debt Debt-to-Equity RatioN/A Current Ratio8.88 Quick Ratio7.96 Sales & Book Value Annual Sales$100.25 million Price / Sales9.96 Cash FlowN/A Price / Cash FlowN/A Book Value$6.53 per share Price / Book3.40Miscellaneous Outstanding Shares44,990,000Free Float42,606,000Market Cap$998.33 million OptionableN/A Beta3.37 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:BBNX) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | SponsoredWhy I believe the AI market will split in Q4Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...The Oxford Club | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredOn October 7th, your “safest” assets are at riskJeff Brown called Nvidia's rise of over 27,000 percent and warned in early 2024 that inflation would outlast W...Brownstone Research | SponsoredWhile SpaceX Gets the Spotlight, FJET Is Building What Comes Next!Starfighters Space (NYSE: FJET) operates the world's only commercial fleet of flight-ready Mach 2+ F-104 Starf...Trading Wire | SponsoredThe REAL Reason 2,000 Missiles Rained on IranTwo private meetings with U.S. Congressmen and weeks of research point to a surprising explanation for the rec...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beta Bionics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Beta Bionics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
